Page last updated: 2024-11-02

pioglitazone and Bone Loss, Perimenopausal

pioglitazone has been researched along with Bone Loss, Perimenopausal in 2 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Samadfam, R1
Awori, M1
Bénardeau, A1
Bauss, F1
Sebokova, E1
Wright, M1
Smith, SY1
Eckert, S1
Erdmann, E1
Lundershausen, R1
Forst, T1
Scherbaum, WA1
Schnell, O1
Standl, E1
Schumm-Draeger, PM1
Tschöpe, D1
Walter, H1
Weber, M1

Other Studies

2 other studies available for pioglitazone and Bone Loss, Perimenopausal

ArticleYear
Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats.
    The Journal of endocrinology, 2012, Volume: 212, Issue:2

    Topics: Adiposity; Animals; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone

2012
[Determining the current position regarding the value of pioglitazone for the therapy of diabetes].
    Deutsche medizinische Wochenschrift (1946), 2007, Volume: 132, Issue:49

    Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fractures, Bone; Glycate

2007